These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 30137336)

  • 1. Utility of HIV-1 DNA genotype in determining antiretroviral resistance in patients with low or undetectable HIV RNA viral loads.
    Boukli N; Boyd A; Collot M; Meynard JL; Girard PM; Morand-Joubert L
    J Antimicrob Chemother; 2018 Nov; 73(11):3129-3136. PubMed ID: 30137336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Niubó J; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2012; 17(3):577-83. PubMed ID: 22301439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa.
    Etta EM; Mavhandu L; Manhaeve C; McGonigle K; Jackson P; Rekosh D; Hammarskjold ML; Bessong PO; Tebit DM
    AIDS Res Ther; 2017 Jul; 14(1):36. PubMed ID: 28750647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1C proviral DNA for detection of drug resistance mutations.
    Huruy K; Mulu A; Liebert UG; Maier M
    PLoS One; 2018; 13(10):e0205119. PubMed ID: 30286160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART.
    Chew CB; Potter SJ; Wang B; Wang YM; Shaw CO; Dwyer DE; Saksena NK
    J Clin Virol; 2005 Jul; 33(3):206-16. PubMed ID: 15911442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
    Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
    AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing Antiretroviral Therapy in Heavily ART-Experienced Patients with Multi-Class Resistant HIV-1 Using Proviral DNA Genotypic Resistance Testing.
    Rauschning D; Ehren I; Heger E; Knops E; Fätkenheuer G; Suárez I; Lehmann C
    Viruses; 2023 Jun; 15(7):. PubMed ID: 37515133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proviral DNA as a Target for HIV-1 Resistance Analysis.
    Lübke N; Di Cristanziano V; Sierra S; Knops E; Schülter E; Jensen B; Oette M; Lengauer T; Kaiser R
    Intervirology; 2015; 58(3):184-9. PubMed ID: 26139571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication.
    Delaugerre C; Braun J; Charreau I; Delarue S; Nere ML; de Castro N; May T; Marchou B; Simon F; Molina JM; Aboulker JP;
    HIV Med; 2012 Oct; 13(9):517-25. PubMed ID: 22416781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients.
    Re MC; Vitone F; Biagetti C; Schiavone P; Alessandrini F; Bon I; de Crignis E; Gibellini D
    Clin Microbiol Infect; 2010 Jun; 16(6):640-6. PubMed ID: 19732081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA.
    Zaccarelli M; Santoro MM; Armenia D; Borghi V; Gennari W; Gori C; Forbici F; Bertoli A; Fabeni L; Giannetti A; Cicalini S; Bellagamba R; Andreoni M; Mastroianni CM; Mussini C; Ceccherini-Silberstein F; Perno CF; Antinori A
    J Clin Virol; 2016 Sep; 82():94-100. PubMed ID: 27472519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Different Antiretroviral Strategies on Total HIV-DNA Level in Virologically Suppressed HIV-1 Infected Patients.
    Bon I; Calza L; Musumeci G; Longo S; Bertoldi A; D'Urbano V; Gibellini D; Magistrelli E; Viale PL; Re MC
    Curr HIV Res; 2017; 15(6):448-455. PubMed ID: 29210661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.
    Saracino A; Gianotti N; Marangi M; Cibelli DC; Galli A; Punzi G; Monno L; Lazzarin A; Angarano G;
    J Med Virol; 2008 Oct; 80(10):1695-706. PubMed ID: 18712823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dual-target approach in viral HIV-1 viremia testing: An added value to virological monitoring?
    Amendola A; Sberna G; Forbici F; Abbate I; Lorenzini P; Pinnetti C; Antinori A; Capobianchi MR
    PLoS One; 2020; 15(2):e0228192. PubMed ID: 32023284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia.
    Seclén E; Del Mar González M; De Mendoza C; Soriano V; Poveda E
    J Antimicrob Chemother; 2010 Jul; 65(7):1493-6. PubMed ID: 20488982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.
    Barth RE; Aitken SC; Tempelman H; Geelen SP; van Bussel EM; Hoepelman AI; Schuurman R; Wensing AM
    Antivir Ther; 2012; 17(2):377-86. PubMed ID: 22297391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinctive Drug-resistant Mutation Profiles and Interpretations of HIV-1 Proviral DNA Revealed by Deep Sequencing in Reverse Transcriptase.
    Yin QQ; Li ZP; Zhao H; Pan D; Wang Y; Xu WS; Xing H; Feng Y; Jiang SB; Shao YM; Ma LY
    Biomed Environ Sci; 2016 Apr; 29(4):239-47. PubMed ID: 27241734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of a long-term discrepancy in drug-targeted genes in plasma HIV-1 RNA and PBMC HIV-1 DNA in the same patient.
    Usuku S; Noguchi Y; Sakamoto M; Adachi T; Sagara H; Sudo K; Nishizawa M; Kondo M; Tochikubo O; Imai M
    Jpn J Infect Dis; 2006 Apr; 59(2):122-5. PubMed ID: 16632914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.